Amgen Sees Acceleration In US Biosimilars Market
Landscape Is ‘Advancing Faster Than EU During A Comparable Period’, Report Indicates
Executive Summary
The US marketplace for biosimilars is accelerating faster than the EU at a similar point in its existence, based on approval rates, Amgen has observed in a preview of its 2022 trends in biosimilars report that also offers new data on pricing and uptake.
You may also be interested in...
Generics Bulletin Editor’s Picks For Q2 2022
Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.
Samsung Bioepis Goes After Lucentis With 40% Cheaper Byooviz Launch In US
Samsung Bioepis and Biogen have come in with a hefty discount as they mark a major milestone by launching their Byooviz biosimilar ranibizumab rival to Lucentis in the US.
US Biosimilars Enjoy A Year Of Firsts In 2021
While US biosimilar approvals have been somewhat thin on the ground in 2021 – with multiple products seeing action delayed due to the FDA’s inability to conduct certain facility inspections during the COVID-19 pandemic – the market has nevertheless seen several firsts this year, including two interchangeability designations and the first ophthalmic biosimilar approval.